“As this shifts from pandemic to endemic, we think there’s an opportunity here for us,” said Pfizer’s Chief Financial Officer Frank D’Amelio.

By Kenny Stancil, staff writer for Common Dreams. Published 3-19-2021

Photo: KALW/CC

Eager to capitalize on the lasting presence of the coronavirus, executives at Johnson & Johnson, Moderna, and Pfizer—the pharmaceutical corporations that supplied the Covid-19 vaccines approved for use in the U.S.—are quietly planning to hike prices on doses “in the near future,” once they decide the pandemic is over, The Intercept’s Lee Fang reported Thursday.

Although the rapid development of coronavirus vaccines—made possible by large infusions of public resources—has given Big Pharma companies “a boost in goodwill… the public is still sensitive to drug pricing and the reputational risk has, so far, curtailed their ability to reap large financial rewards,” Fang noted. “But that environment, they hope, will change once the pandemic ends: a date that drugmakers themselves reserve the right to declare.” Continue reading →